Caisse Des Depots ET Consignations Trims Holdings in Harrow, Inc. $HROW

Caisse Des Depots ET Consignations reduced its stake in Harrow, Inc. (NASDAQ:HROW) by 68.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,515 shares of the company’s stock after selling 12,007 shares during the period. Caisse Des Depots ET Consignations’ holdings in Harrow were worth $266,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of HROW. Profund Advisors LLC purchased a new position in shares of Harrow during the 3rd quarter worth $328,000. Oppenheimer & Co. Inc. increased its position in Harrow by 12.6% during the third quarter. Oppenheimer & Co. Inc. now owns 14,994 shares of the company’s stock worth $722,000 after purchasing an additional 1,677 shares during the last quarter. Independent Advisor Alliance purchased a new position in Harrow during the third quarter worth about $210,000. AlphaQuest LLC raised its stake in Harrow by 743.0% during the third quarter. AlphaQuest LLC now owns 3,819 shares of the company’s stock worth $184,000 after purchasing an additional 3,366 shares during the period. Finally, Great Lakes Advisors LLC boosted its holdings in Harrow by 4.0% in the 3rd quarter. Great Lakes Advisors LLC now owns 26,963 shares of the company’s stock valued at $1,299,000 after purchasing an additional 1,035 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HROW has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH raised their price target on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $94.00 price target on shares of Harrow in a research note on Tuesday, November 11th. HC Wainwright raised their price objective on Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.43.

Harrow Stock Down 3.2%

NASDAQ:HROW opened at $47.12 on Friday. Harrow, Inc. has a 52 week low of $20.85 and a 52 week high of $54.85. The stock’s fifty day moving average is $47.56 and its two-hundred day moving average is $42.21. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -471.15 and a beta of 0.07. The company has a quick ratio of 2.52, a current ratio of 2.72 and a debt-to-equity ratio of 5.21.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.11. Harrow had a positive return on equity of 28.71% and a negative net margin of 1.99%.The firm had revenue of $71.64 million for the quarter, compared to the consensus estimate of $73.70 million. Research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.